LINC01433 promotes hepatocellular carcinoma progression via modulating the miR-1301/STAT3 axis

Long noncoding RNAs (lncRNAs) have been demonstrated to play significant roles in hepatocellular carcinoma (HCC) tumor progression. LINC01433 has been implicated in the progression of lung cancer. However, its biological role in HCC remains poorly understood. In our current study, we focused on the detailed mechanism of LINC01433 in HCC development. First, it was exhibited that LINC01433 was remarkably elevated in HCC cells, which indicated that LINC01433 was involved in HCC. Then, knockdown of LINC01433 was able to restrain HCC cell proliferation and cell colony formation and greatly induced cell apoptosis. On the contrary, overexpression of LINC01433 promoted HCC cell proliferation, increased cell colony formation, and enhanced cell invasion capacity. Subsequently, we found that miR-1301 was remarkably decreased in HCC cells, and it can serve as a target of LINC01433 according to bioinformatics analysis. In addition, the binding correlation between them was validated by performing RNA pull-down experiments and RIP assay. Moreover, STAT3 was predicted and validated as a target of miR-1301, and it was shown that miR-1301 mimics significantly suppressed STAT3 in HCC cells. Finally, in vivo models were established, and the results demonstrated that silencing of LINC01433 could repress HCC development through modulating miR-1301 and STAT3. Taken together, these results indicated in our study that LINC01433 participated in HCC progression through modulating the miR-1301/STAT3 axis and it might act as a novel biomarker in HCC diagnosis and treatment.     

Divergent intracellular pathways regulate interleukin-1β-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells

We have previously reported that IL-β-induced miR-146a and miR-146b expression negatively regulates IL-8 and RANTES release in human alveolar A549 epithelial cells. To determine the intracellular pathways that regulate this response, we demonstrate IL-1β-induced activation of the nuclear factor (NF)-κB, extracellular regulated kinase (ERK)-1/2, c-jun N-terminal kinase (JNK)-1/2 and p38 mitogen activated kinase (MAP) kinase pathways. Subsequent pharmacological studies show that IL-1β-induced miR-146a, IL-8 and RANTES production was regulated via NF-κB and JNK-1/2 whilst miR-146b expression was mediated via MEK-1/2 and JNK-1/2. These divergent intracellular pathways likely explain the differential expression and biological action of the miR-146 isoforms.     

LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR-129-3p to activate STAT3 and PD-L1

Immune escape of renal cell carcinoma (RCC) impacts patient survival. However, the molecular mechanism of long noncoding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) in RCC immune escape remains unclear. Quantitative real-time PCR and western blotting results revealed that the expression of lncRNA SNHG1 and STAT3 were upregulated in RCC tissues and cells and that the expression of miR-129-3p was downregulated. Enzyme-linked immunosorbent assay results revealed the increased levels of immune-related factors (interferon-γ, tumour necrosis factor α, and interleukin-2) in RCC tissues. SNHG1 knockdown or miR-129-3p overexpression inhibited the proliferation and invasion of A498 and 786-O cells, while the proliferation and cytotoxicity of CD8⁺ T cells increased, which promoted the secretion of immune-related factors. STAT3 overexpression decreased the protective effect of miR-129-3p overexpression on RCC cell immune escape. In addition, miR-129-3p knockdown and STAT3 overexpression decreased the protective effect of lncRNA SNHG1 knockdown on RCC cell immune escape. In addition, PD-L1 expression was downregulated after lncRNA SNHG1 knockdown but upregulated after miR-129-3p knockdown and STAT3 overexpression. Dual-luciferase assays showed that lncRNA SNHG1 targets miR-129-3p, and miR-129-3p targets STAT3. RNA pull-down and RNA immunoprecipitation assays verified the regulatory relationship between SNHG1 and STAT3. In vivo, shSNHG1 prolonged the overall survival of RCC tumour model mice and inhibited RCC tumour growth and immune escape but increased CD8⁺ T cell infiltration in mice. Our findings provide an experimental basis for elucidating the molecular mechanisms of immune escape by RCC and reveal a novel target to treat this disease.     

The clinical significance of circulating miR-21, miR-142, miR-143, and miR-146a in patients with prostate cancer

BackgroundProstate cancer (PCa) is the most common type of solid tissue cancer among men in western countries. In this study, we determined the levels of circulating miR-21, miR-142, miR-143, miR-146a, and RNU 44 levels as controls for early diagnosis of PCa.MethodsThe circulating miRNA levels in peripheral blood samples from 43 localized PCa patients, 12 metastatic PCa (MET) patients, and a control group of, 42 benign prostate hyperplasia (BPH) patients with a total of 97 volunteers were determined the by PCR method.ResultsNo differences in the DCT values were found among the groups. In PCa and PCaMet groups the expression of miR21 and miR142 were higher compared to the BHP group. No other differences were observed among the other groups. miR21 expression in the PCa group was 6.29 folds upregulated whereas in the PCaMet group 10.84 folds up-regulated. When the total expression of miR142 is evaluated, it showed a positive correlation with mir21 and mir 146 (both p<0.001). Also, the expression of miR146 shows a positive correlation with both miR21 and miR143 (both p<0.001). Expression of miRNAs was found to be an independent diagnostic factor in patients with Gleason score, PSA, and free PSA levels.ConclusionsOur study showed that co-expression of miR21, miR-142, miR-143, and miR-146a and the upregulation of miR-21 resulted in increased prostate carcinoma cell growth. In the PCaMet group, miR21 is the most upregulated of all miRNAs. These markers may provide a novel diagnostic tool to help diagnose PCa with aggressive behavior.     

骨碎补对骨性关节炎患者骨关节滑膜组织中miR-27a、miR-146a表达的影响

目的:探讨骨碎补对骨性关节炎患者骨关节滑膜组织中mi R-27a、mi R-146a表达的影响。方法:选取我院收治的骨性关节炎患者46例,随机分为两组,每组各23例。对照组予抗骨增生治疗,实验组在对照组基础上加以骨碎补治疗。观察和比较两组患者的临床疗效、炎性因子水平的变化以及骨关节滑膜组织中mi R-27a、mi R-146a的表达情况。结果:1治疗后,两组患者的临床症状均有所改善,且实验组疗效高于对照组,差异有统计学意义(P0.05)。2治疗后,两组患者的IL-1β、PGE2水平均较治疗前显著降低,且实验组降低较对照组更明显,差异均有统计学意义(P0.05)。3治疗后,两组患者的骨关节滑膜组织中的mi R-27a、mi R-146a表达均降低,且与对照组比较,实验组较低,差异有统计学意义(P0.05)。结论:骨碎补能够降低骨性关节炎患者骨关节滑膜组织中mi R-27a、mi R-146a的表达,降低IL-1β、PGE2的水平,提高临床疗效。     

非小细胞肺癌患者血清miR-146a、miR-141的表达及临床意义

目的:研究非小细胞肺癌(NSCLC)患者血清微小RNA-146a(mi R-146a)、mi R-141的表达及临床意义。方法:选取2015年1月至2018年1月我院收治的106例NSCLC患者记为NSCLC组,另选取同期于我院进行体检的40例健康体检者记为健康对照组。采用荧光实时定量PCR(qRT-PCR)检测两组血清mi R-146a、mi R-141的表达水平,分析NSCLC患者血清mi R-146a、mi R-141表达水平与临床病理参数的关系,比较血清mi R-146a、mi R-141单一诊断及联合诊断NSCLC的曲线下面积(AUC)、灵敏度、特异度。结果:NSCLC组患者的血清mi R-146a、mi R-141表达水平高于健康对照组(P0.05)。NSCLC患者血清mi R-146a表达水平与病理分期有关(P0.05),与年龄、性别、吸烟史、病理类型、病理分级、肿瘤直径及是否伴有淋巴结转移无关(P0.05)。NSCLC患者血清mi R-141表达水平与病理分期、病理分级及是否伴有淋巴结转移有关(P0.05),与年龄、性别、吸烟史、病理类型、肿瘤直径无关(P0.05)。血清mi R-146a、mi R-141单一诊断及两者联合诊断NSCLC的AUC分别为0.841、0.772、0.921,敏感度分别为85.1%、80.5%、93.5%,特异度分别为84.2%、75.3%、89.8%。结论:NSCLC患者血清mi R-146a、mi R-141表达水平升高,且与部分临床病理参数有关,两者联合检测对NSCLC诊断具有较高的诊断价值。     

特应性皮炎患儿外周血miR-122a和miR-146a水平与Th1/Th2/Th17免疫平衡的相关性分析

摘要 目的：探讨特应性皮炎（AD）患儿外周血微小核糖核酸（miRNA）-122a和miR-146a水平与辅助性T细胞（Th）1/Th2/Th17免疫平衡的相关性。方法：选取2020年5月～2023年5月石家庄市妇幼保健院皮肤科收治的AD患儿100例为AD组,根据特应性皮炎评分（SCORAD）分为轻度组31例、中度组41例、重度组28例,另选取同期100名体检健康儿童为对照组。采用实时荧光定量聚合酶链式反应检测外周血miR-122a、miR-146a水平,流式细胞术检测外周血Th1、Th2、Th17细胞比例,酶联免疫吸附法检测外周血Th1、Th2、Th17相关细胞因子[白细胞介素（IL）-2、干扰素-γ（IFN-γ）、IL-4、IL-13、IL-17、IL-22]水平,并计算Th1/Th2/Th17比值。采用Pearson/Spearman相关性分析AD患儿外周血miR-122a、miR-146a与Th1、Th2、Th17和相关细胞因子及Th1/Th2/Th17的相关性。结果：AD组外周血miR-122a、miR-146a、Th1、Th1/Th2/Th17、IL-2、IFN-γ水平低于对照组,Th2、Th17、IL-4、IL-13、IL-17、IL-22水平高于对照组（P均＜0.05）。轻度组、中度组、重度组外周血miR-122a、miR-146a、Th1、Th1/Th2/Th17、IL-2、IFN-γ水平依次降低,Th2、Th17、IL-4、IL-13、IL-17、IL-22水平依次升高（P均＜0.05）。Pearson/Spearman相关性分析显示,AD患儿外周血miR-122a、miR-146a与Th1、Th1/Th2/Th17、IL-2、IFN-γ水平呈正相关（r/rs分别为0.679、0.677、0.684、0.706、0.693、0.689、0.671、0.694,P均＜0.001）,与Th2、Th17、IL-4、IL-13、IL-17、IL-22呈负相关（r/rs分别为-0.690、-0.680、-0.681、-0.669、-0.675、-0.676、-0.676、-0.686、-0.682、-0.674、-0.680、-0.689,P均＜0.001）。结论：AD患儿外周血miR-122a、miR-146a水平降低,与病情严重程度密切相关,可能通过调节Th1/Th2/Th17免疫平衡参与AD发生发展。     

Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

1. Download : Download high-res image (123KB)
2. Download : Download full-size image

     

miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90

Cancer stem cells promote tumorigenesis and progression of hepatocellular carcinoma (HCC). Recently, emerging evidence indicates tumor-associated macrophages (TAMs) play an important role in tumor progression. However, TAMs often occurs with unknown mechanisms. As an important mediator in intercellular communications, exosomes secreted by host cells mediate the exchange of genetic materials and proteins, which involves tumor aggressiveness. The aim of the study was to investigate whether exosomes derived from TAMs mediate stem cell properties in HCC. TAMs were isolated from the tissues of HCC. microRNA (miRNA) expression profiles of TAMs were analyzed using miRNA microarray. In vitro cell coculture was further conducted to investigate the crosstalk between TAMs and tumor cells mediated by TAMs exosomes. In this study, we showed that TAMs exosomes promote HCC cell proliferation and stem cell properties. Using miRNA profiles assay, we identified significantly lower levels of miR-125a and miR-125b in exosomes and cell lysate isolated from TAMs. Functional studies revealed that the HCC cells were treated with TAM exosomes or transfected with miR-125a/b suppressed cell proliferation and stem cell properties by targeting CD90, a stem cell marker of HCC stem cells. The study indicated that miR-125a/b targeting CD90 played important roles in cancer stem cells of HCC.     

Altered expression patterns of complement factor H and miR-146a genes in acute-chronic phases in experimental autoimmune encephalomyelitis mouse

Considerable advances have been made in identification of the involvement of immune modulators in diseases. There is growing evidence on the role of complement pathway in pathogenesis and course of multiple sclerosis (MS). Moreover, it has been recognized that microRNAs (miRNAs) play an essential role in modulation and development of immune response in the central nervous system. We aimed to investigate the expression profile of complement factor H (CFH) and miR-146a genes in experimental autoimmune encephalomyelitis (EAE) mouse model of MS to detect the possible roles of CFH and miR-146a as biomarkers of MS disease stats. Expression of CFH and miR-146a genes in liver and brain tissues of EAE mice was measured in acute and chronic phases of disease compared to matched controls using real-time polymerase chain reaction. In the liver, increased expression of CFH gene was observed in the chronic phase compared to the acute phase. However, no significant difference was observed between acute and chronic phase mice with normal mice, while miR-146a expression was significantly decreased in livers of EAE mice in chronic group compared to acute and control groups. The expression of CFH gene in brain had a significant decrease in acute and chronic phases compared to healthy mice. Taken together, these observations indicate probable implication of complement system and miR-146a in course of immune-related diseases and reveal more facts about the pathogenesis of MS. However, further work is needed to determine protein levels of CFH and other possible targets of miR-146a in serum and cerebrospinal fluid of MS patients.     

Down-regulation of CD3zeta is a breast cancer biomarker associated with immune suppression

This work was done to establish a correlation between serum protein expression profiles and breast cancer. A high-density antibody microarray was used to identify serum protein expression profiles. Proteins up- or down-regulated by 2-fold compared with normal controls were used for hierarchical clustering analysis. ELISA and immunohistochemistry were used for validation of protein array data. The CD3zeta chain was one of the down-regulated molecules identified by the antibody array analysis and confirmed by ELISA and immunohistochemistry. The mean CD3zeta levels in breast cancer and in normal control were 119±23 and 156±35 ng/ml, respectively. The AUC (area under the curve) of CD3zeta was 0.837±0.057. Forty-one out of 65 breast cancer cases (63.08%) showed reduced CD3zeta expression on tumour-infiltrating lymphocytes by immunohistochemistry. This is the first report describing down-regulation of CD3zeta expression on breast cancer for the Chinese population and suggests that an immunosuppressive status plays an important role in breast cancer progression.